Down-regulation of antihost alloreactivity after bone marrow transplant permits relapse of hematological malignancy

Cancer Research

Volumn 62, Issue 1, 2002, Pages 208-212

  Wang, Jun ^a   Shaw, Joanne L ^a   Mullen, Craig A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTOCOMPATIBILITY ANTIGEN;

ALLOIMMUNITY; ANIMAL CELL; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GRAFT VERSUS HOST REACTION; IMMUNE RESPONSE; IN VITRO STUDY; LEUKEMIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 0036143021     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms
2. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia
3. Graft-versus-leukemia reactions after bone marrow transplantation
4. Current trends in BMT
5. Bone Marrow Transpl.
6. Immunization of allogeneic bone marrow transplant recipients with tumor cell vaccines enhances graft-versus-tumor activity without exacerbating graft-versus-host disease
7. Enhancement of graft-versus-tumor activity and graft-versus-host disease by pretransplant immunization of allogeneic bone marrow donors with a recipient-derived tumor cell vaccine
8. The minor histocompatibility antigen HA-1: A dialielic gene with a single amino acid polymorphism
9. Much ado about minor histocompatibility antigens
10. HA-1 and the SMCY-derived peptide FIDSYICQV (H-Y) are immunodommant minor histocompatibility antigens after bone marrow transplantation
11. Genomic identification of the minor histocompatibility antigen HA-1 locus by allele-specific PCR
12. Cutting edge: The HLA-A*0101-restricted HY minor histocompatibility antigen originates from DFFRY and contains a cysteinylated cysteine residue as identified by a novel mass spectrometric technique
13. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens
14. A transplantable mast-cell neoplasm in the mouse
15. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. 1. Rejection by syngeneic mice
16. Fas and Fas ligand interactions suppress melanoma lung metastasis
17. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells
18. Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease
19. Immune selection after antigen-specific immunotherapy of melanoma
20. Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immuno-suppression
21. Mechanisms of syngeneic tumor rejection. Susceptibility of host-selected progressor variants to various immunological effector cells
22. Pecking order among tumor-specific antigens
23. Stepwise immunologic selection of antigenic variants during tumor growth
24. Major histocompatibility complex class I and unique antigen expression by murine tumors that escaped from CD8+ T-cell- dependent surveillance
25. Immune escape from a graft-versus-leukemia effect may play a role in the relapse of myeloid leukemias following allogeneic bone marrow transplantation
26. Mechanisms of tolerance
27. Relapse of host leukemic lymphoblasts following engraftment by an HLA-mismatched marrow transplant: Mechanism of escape from the "graft versus leukemia" effect